Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Galectin Therapeutics (NASDAQ: GALT) has announced that the top-line results of their NAVIGATE trial, focusing on patients with MASH cirrhosis and portal hypertension, will be presented at the 2025 MASH-TAG Conference in Park City, Utah, from January 9-11, 2025.
The presentation, titled "Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial," will be delivered by Dr. Naim Alkhouri, Chief Medical Officer of Arizona Liver Health, on January 10, 2025, at 11:25 AM MST.
Additionally, the company's executive leadership will host one-on-one meetings in San Francisco during the JP Morgan Healthcare Conference from January 13-16, 2025, to discuss NAVIGATE topline results and future steps for the belapectin program with external stakeholders.
Galectin Therapeutics (NASDAQ: GALT) ha annunciato che i risultati preliminari del loro trial NAVIGATE, che si concentra su pazienti con cirrosi MASH e ipertensione portale, verranno presentati alla 2025 MASH-TAG Conference a Park City, Utah, dal 9 all'11 gennaio 2025.
La presentazione, intitolata "Belapectin somministrato a 2mg/kg/LBW per 18 mesi ha ridotto l'incidenza dello sviluppo di varici nei pazienti con cirrosi MASH e ipertensione portale: Risultati preliminari del trial NAVIGATE", sarà tenuta dal Dr. Naim Alkhouri, Chief Medical Officer di Arizona Liver Health, il 10 gennaio 2025, alle 11:25 MST.
Inoltre, i dirigenti dell'azienda organizzeranno incontri individuali a San Francisco durante il JP Morgan Healthcare Conference dal 13 al 16 gennaio 2025, per discutere i risultati preliminari del NAVIGATE e i futuri sviluppi del programma di belapectin con i soggetti esterni.
Galectin Therapeutics (NASDAQ: GALT) ha anunciado que los resultados iniciales de su ensayo NAVIGATE, centrado en pacientes con cirrosis MASH e hipertensión portal, se presentarán en la 2025 MASH-TAG Conference en Park City, Utah, del 9 al 11 de enero de 2025.
La presentación, titulada "Belapectin administrado a 2mg/kg/LBW durante 18 meses redujo la incidencia del desarrollo de varices en pacientes con cirrosis MASH e hipertensión portal: Resultados iniciales del ensayo NAVIGATE", será presentada por el Dr. Naim Alkhouri, Chief Medical Officer de Arizona Liver Health, el 10 de enero de 2025, a las 11:25 AM MST.
Además, el liderazgo ejecutivo de la empresa llevará a cabo reuniones uno a uno en San Francisco durante el JP Morgan Healthcare Conference del 13 al 16 de enero de 2025, para discutir los resultados iniciales del NAVIGATE y los pasos futuros del programa de belapectin con partes interesadas externas.
Galectin Therapeutics (NASDAQ: GALT)는 MASH 간경변 및 문맥 고혈압 환자를 대상으로 한 NAVIGATE 시험의 주요 결과를 2025년 1월 9일부터 11일까지 유타주 파크시티에서 열리는 2025 MASH-TAG Conference에서 발표한다고 발표했습니다.
제목은 "18개월 동안 2mg/kg/LBW로 투여된 Belapectin이 MASH 간경변 및 문맥 고혈압 환자에서 변성 발생의 빈도를 감소시켰다: NAVIGATE 시험의 주요 결과"로, 아리조나 간 건강의 최고 의료 책임자 Naim Alkhouri 박사가 2025년 1월 10일 오전 11:25 MST에 발표합니다.
또한, 회사의 경영진은 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 JP Morgan Healthcare Conference 동안 외부 이해관계자와 NAVIGATE 주요 결과 및 belapectin 프로그램의 향후 조치를 논의하기 위해 일대일 회의를 주최할 예정입니다.
Galectin Therapeutics (NASDAQ: GALT) a annoncé que les résultats préliminaires de leur essai NAVIGATE, axé sur les patients atteints de cirrhose MASH et d'hypertension portale, seront présentés lors de la 2025 MASH-TAG Conference à Park City, Utah, du 9 au 11 janvier 2025.
La présentation, intitulée "Belapectin administré à 2mg/kg/LBW pendant 18 mois a réduit l'incidence du développement de varices chez les patients atteints de cirrhose MASH et d'hypertension portale : Résultats préliminaires de l'essai NAVIGATE", sera faite par le Dr Naim Alkhouri, Directeur médical d'Arizona Liver Health, le 10 janvier 2025 à 11h25 MST.
De plus, la direction de l'entreprise organisera des réunions individuelles à San Francisco lors de la JP Morgan Healthcare Conference du 13 au 16 janvier 2025, pour discuter des résultats préliminaires de NAVIGATE et des prochaines étapes du programme Belapectin avec les parties prenantes externes.
Galectin Therapeutics (NASDAQ: GALT) hat bekannt gegeben, dass die vorläufigen Ergebnisse ihrer NAVIGATE-Studie, die sich auf Patienten mit MASH-Zirrhose und portaler Hypertension konzentriert, auf der 2025 MASH-TAG-Konferenz in Park City, Utah, vom 9. bis 11. Januar 2025 präsentiert werden.
Die Präsentation mit dem Titel "Belapectin, verabreicht mit 2mg/kg/LBW über 18 Monate, reduzierte die Inzidenz von Varizen bei Patienten mit MASH-Zirrhose und portaler Hypertonie: Vorläufige Ergebnisse aus der NAVIGATE-Studie", wird Dr. Naim Alkhouri, Chief Medical Officer von Arizona Liver Health, am 10. Januar 2025 um 11:25 Uhr MST halten.
Darüber hinaus wird die Unternehmensführung während der JP Morgan Healthcare Conference vom 13. bis 16. Januar 2025 in San Francisco Einzelgespräche führen, um die vorläufigen Ergebnisse von NAVIGATE und die nächsten Schritte für das Belapectin-Programm mit externen Interessengruppen zu erörtern.
- None.
- None.
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looking forward to engaging external stakeholders on NAVIGATE topline results and discussing next steps for the belapectin program.
Presentation details
Title: Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial
Presenter: Naim Alkhouri, M.D., Chief Medical Officer, Arizona Liver Health, Chandler, AZ
Format: Oral presentation
Session: Deep Dive into Incretin and Endocrine Based Therapies
Date & Time: January 10, 2025 at 11:25 AM MST
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
What are the key findings of Galectin Therapeutics' NAVIGATE trial for MASH cirrhosis?
When and where will Galectin Therapeutics (GALT) present their NAVIGATE trial results?
What is the dosage and duration of belapectin treatment in the NAVIGATE trial?
Where will Galectin Therapeutics (GALT) hold investor meetings following the MASH-TAG presentation?
Who will present the NAVIGATE trial results at the 2025 MASH-TAG Conference?
